Replies to post #110776 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

SUPER DUPER WHOOPER POOPER WRONG!
Here follow up!
Did you know that Pterostilbene inhibits tumor growth, progression and metastasis?....contact us for more information [phone] www.panamcancerclinic.com
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057542
HemaXellerate’s approval and clearance by the FDA to commence Human Trials with the New Drug. That resulted in two things. One RGBP transitioned from a R&D company, morphing into a Clinical Trials Company, a major step in the progress of the company and credibility.

Second RGBP attracted their first viable partner as the (NIH) agency NCATS agreed to collaborate with clinical trials using HemaXellerate for a treatment of the rare blood disease/disorder aPlastic Anemia.

New Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company –

Weill Cornell Medical College (Cornell University)
HemaXellerate II was discovered to be effective in treating an additional market much more vast than aPlastic Anemia. It is in the early stage of development to treat Bone Marrow Suppression, a common disorder due to Chemotherapy. This finding occurred at/with another new partner The Pan Am Cancer Research and Treatment Center where ongoing Trials are being conducted.

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

dCell Vax (Treatment for Breast Cancer) seems to be at last news in the final comments with the FDA to gain approval to commence Human Trials with Breast Cancer Patients.

The NIH (NCATS) also is collaborating with Regen and working together to screen small molecule compounds that activate or inhibit orphan nuclear receptor, NR2F6 (Research Project), cell lines will be provided by Regen. Regen also has a partnership with Eli Lily working together with NR2F6.

For all the news-Details on other treatments HemaXellerate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, uCell Vax, Car-T Cell for various different Cancers, Autoimmune, rare Blood Disorders/Diseases, Leukemia, etc.

[pumper_stumper]

Since RGBP is in the pinks, home of the least effective due diligence on the planet, what % of RGBP shareholders do you think assume a provisional patent (the latest PR) means their patent reviewed and approved?

I say 95%!

And thanks for debunking that misinformation there! You opened up many eyes with those facts!